ONY   Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Amherst NY United States (1985)

Organization Overview

First Clinical Trial
2005
NCT00599651
First Marketed Drug
1998
calfactant (infasurf)
First NDA Approval
1998
calfactant (infasurf)
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Ony | ONY | ONY Biotech Inc.

Active Ingredients

Marketed Drugs (1)

calfactant (infasurf) (1998 NDA)

Drugs in Phase 4 Trials (1)

remifentanil (ultiva) (1 trial)

Drugs in Phase 3 Trials (1)

calfactant (infasurf) (5 trials)

Drugs in Other Trials (1)

oxygen (1 trial)

Indications

Approved Indications


 

Respiratory Distress Syndrome, Newborn

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchiolitis (Phase 1)

Bronchopulmonary Dysplasia (Phase 3)

Premature Birth (Phase 3)

Respiratory Distress Syndrome (Phase 4)

Respiratory Distress Syndrome, Newborn (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 3